1 report

  • Jun 22, 2017: Infectex Successfully Completes Phase 1 Clinical Study of Q203 for Treatment of Tuberculosis
  • Qurient Raises USD25.7 Million in IPO

" Q## is undergoing intensive phase ## testing and demonstrates excellent results in all studies, including one that is completed by our partner Infectex", - said Dr.

  • Healthcare
  • Pharmaceutical
  • Tuberculosis
  • South Korea
  • Qurient Co., Ltd.